Skip to main content
Back
Watch Compare

CNS Pharmaceuticals, Inc.

Data quality: 83%
CNSP
NASDAQ Manufacturing Chemicals
$2.18
▼ $0.04 (-1.80%)
Mkt Cap: 1.80 M
Price
$2.22
Mkt Cap
1.80 M
Day Range
—
52-Week Range
—
Volume
—
Open —
50D / 200D Avg
—
50D / 200D Avg
—

Quick Summary

Key Takeaways

Negative free cash flow of -13.83 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-137.62%
Below sector avg (-54.47%)
ROIC-109.65%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio5.81
Interest Coverage-1049.68

Valuation

PE (TTM)
-0.11
Above sector avg (-1.49)
P/B Ratio0.18
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1385 peers)
Metric Stock Sector Median
P/E -0.1 -1.5
P/B 0.2 1.6
ROE % -137.6 -54.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.9
D/E — 0.3

Analyst Price Target

1 analyst
Strong Buy
Current
$2.18
+358.7%
Target
$10.00
$10.00
$10.00
$10.00
Forecast
Forward EPS -$2.89
Est. Revenue 0.0

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2027 -$2.89
-$2.89 – -$2.89
 0.0 1
FY2026 -$3.67
-$3.67 – -$3.67
 0.0 1

Earnings Surprises

Last 4 quarters
Quarter Est. EPS Actual EPS Surprise
Q42025 -$5.09 -$10.15 -99.4%
Q32025 -$6.63 -$5.76 +13.1%
Q22025 -$9.60 -$6.42 +33.1%
Q12025 -$24.00 -$18.96 +21.0%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -15.85 M
ROE -137.62% ROA -120.18%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -13.83 M
ROIC -109.65% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 5.81
Interest Coverage -1049.68 Asset Turnover N/A
Working Capital 9.43 M Tangible Book Value 9.91 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.11 Forward P/E N/A
P/B Ratio 0.18 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -767.69%
Market Cap 1.80 M Enterprise Value -8.06 M
Per Share
EPS (Diluted TTM) -35.75 Revenue / Share N/A
FCF / Share -17.04 OCF / Share -17.02
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 87.25%
SBC-Adj. FCF -14.20 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -15.85 M -14.86 M -18.85 M -15.27 M -14.04 M
EPS (Diluted) -35.75 -38.87 -5.00 -11.22 —
Gross Profit — — — — —
Operating Income -15.99 M -14.90 M -18.87 M -15.27 M -14.03 M
EBITDA — — — — —
R&D Expenses 9.77 M 9.29 M 14.10 M 9.30 M 9.35 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense 15,230.0 16,120.0 13,805.0 7,027.0 9,285.0
Income Tax 0.0 0.0 0.0 0.0 0.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 8.62 M 8.70 M 1.70 M 13.05 M 8.76 M
Total Liabilities 4.10 M 2.52 M 6.13 M 4.92 M 2.14 M
Shareholders' Equity 4.52 M 6.18 M -4.43 M 8.13 M 6.62 M
Total Debt — — — 449,874.0 425,990.0
Cash & Equivalents 7.20 M 6.46 M 548,721.0 10.06 M 5.00 M
Current Assets 8.10 M 8.66 M 1.59 M 12.56 M 7.48 M
Current Liabilities 4.10 M 2.52 M 6.13 M 4.92 M 2.14 M